SPI Infoamtion

Table of Contents

Chapter I. Executive Overview of the Space

• Molecular Diagnostics in Cancer:
  Breakout of the Market By Types of Tests and Their Value Proposition
• Prognostic vs. Predictive Markers for Cancer
• Personalized Medicine is Driving Cancer Treatment Decisions TODAY
• Commercialization Metrics: Drugs vs. Diagnostics
• The Lopsided Remuneration for Diagnostics:
  Personalized Medicine is Changing This Paradigm
• Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for Personalized Medicine and Drivers for Market Acceptance
• Trajectory of Genomics-based Cancer Biomarker Tests, such as IDVMIAs, for Personalized Medicine: Drivers and Challenges
• Quantitative Market Metrics: Market Sizes
• The Future of Cancer Personalized Medicine

Chapter II. Emerging Cancer Biomarkers for Personalized Medicine:
mcroRNA-based, Epigenetics-based

• Potential Role of microRNAs and Epigenetics in Cancer Personalized Medicine - The Potential Market Opportunities
• A microRNA Cancer Map
• microRNAs that are Associated with Human Cancers
• microRNAs that may Regulate Cancer-related Genes - I Particular microRNAs may regulate specific cancer genes & their effect on cell function
• microRNAs that may Regulate Cancer-related Genes - II. Alteration of microRNA expression in human malignancies
• Epigenetic Alterations in Cancer
• Predicted Impact of microRNA Diagnostics on Various Disease Areas and Associated Timelines
• Predicted Impact of microRNA Therapeutics on Various Disease Areas and Associated Timelines
• Rosetta Genomics Ltd., A Pioneer in Developing and Commercializing microRNA-based Caner Diagnostics
• Selected Market Participants Developing Epigenetics-based Cancer Personalized Tests

Chapter III. RNAi Therapeutics Landscape for Cancer

Chapter IV. Market Analysis:Cancer Personalized Medicine

• Why Cancer Personalized Medicine?
  Value Delivered by the Diagnostic and Associated Value by the Therapeutic
• Cancer Personalized Medicine:
  Anticancer drugs that can be used together with a pharmacodiagnostic test
• Economics of Cancer Personalized Medicine
• Multigene Predictors of Clinical Outcome for Breast Cancer
• Comparison of Cost of Tests Across the Market Landscape for Breast Cancer Testing
• Personalized Medicine in Other Caners-A Complete Analysis of the Entire Landscape
• Personalized Warfarin Therapy:
  Another Paradigm for the Personalized Medicine Marketplace
• Cancer Personalized Medicine Worldwide Market Survey Data

Chapter V. Industry Participants in Personalized Medicine

• Abbott Molecular
• Affymetrix
• Agendia BV
• Celera
• Cepheid
• Clinical Data: PGXHealth, Cogenics, and Epidauros
• Dako Denmark A/S
• deCODE genetics
• DNA Direct
• DxS Ltd.
• Exact Sciences
• eXagen Diagnositcs
• Gen-Probe
• Genelex
• Genentech
• Genomic Health
• Genzyme Genetics
• Illumina
• Luminex
• Monogram Biosciences
• Myriad Genetics
• Nanogen
• Osmetech Molecular Diagnostics
• Perlegen Sciences
• PGxI Laboratories
• Prometheus Laboratories
• Roche Diagnostics
• Siemens Medical Solutions Diagnostics
• Target Discovery
• Third Wave Technologies
• XDx
• Ventana Medical Systems/Roche

Appendix I. Research Methodology

Appendix II. Drug Metabolism Drives Drug Efficacy / Toxicity

Appendix III. Rigulatory Guidelines in Personalized Medicine